Barcelona, 08 May 2026 – The field of cellular therapies has reached a significant milestone with the successful completion of the first-ever inspection under the third edition Immune Effector Cells (IEC) Standards by JACIE at Guy’s and St Thomas’ NHS Foundation Trust. This achievement not only confirms the robustness of these newly established standards but also marks a pivotal expansion in the certification of cellular therapy programs beyond the traditional domain of stem cell transplantation. As immune effector cell therapies surge forward, this development represents a critical step in aligning clinical innovation with rigorous quality frameworks.
Immune Effector Cell therapies, most famously recognized through CAR-T cell treatments, have revolutionized the management of hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. Recent advancements, however, illustrate a paradigm shift as researchers extend IEC therapies to combat solid tumors and severe autoimmune disorders, indicating vast potential for transforming oncology and immunology. This dynamic landscape has generated an urgent need for comprehensive, dedicated standards that address the complexity and unique challenges inherent in IEC therapy delivery.
In response to this demand, JACIE, in a collaborative effort with the Foundation for the Accreditation of Cellular Therapy (FACT), has co-published the 3rd Edition IEC Standards. These standards represent the first standalone framework meticulously designed to govern IEC programs. Developed over three years by an international panel of experts and officially published in October 2025, they came into effect in February 2026. This milestone reflects a forward-thinking approach to ensure quality and safety as IEC therapies become increasingly mainstream.
The newly introduced IEC certification pathway fundamentally broadens JACIE’s portfolio, moving beyond the confines of hematopoietic cell transplantation. It now encompasses clinical areas where immune effector cells are employed in managing not only hematological diseases but also solid tumors, autoimmune diseases, and contexts involving solid organ transplantation and advanced investigational trials. This strategic expansion aligns with the therapeutic evolution of IEC technologies and ensures that quality oversight keeps pace with clinical advances.
This certification pathway demands a comprehensive approach covering every phase of IEC therapy administration. It spans the entire process — from patient selection criteria through to clinical care, cell collection, intricate manufacturing procedures (including coordination with external manufacturing entities where applicable), product receipt and handling, administration, and crucially, post-infusion monitoring and long-term patient follow-up. Such exhaustive coverage ensures all critical facets unique to IEC treatment are systematically addressed.
Among the distinctive quality parameters emphasized are the chain-of-identity and chain-of-custody processes, which are vital in preventing sample misidentification and ensuring patient safety throughout the therapy lifecycle. Additionally, the standards mandate close coordination with commercial partners, recognizing the often complex supply chains in IEC therapy. There is also a spotlight on identifying and managing therapy-specific toxicities, such as cytokine release syndrome and neurotoxicity, which require specialized clinical expertise and protocols to mitigate risks.
Guy’s and St Thomas’ NHS Foundation Trust had the honor of serving as the pilot site for this landmark inspection. Their commitment to embracing pioneering quality assurance processes provided a critical proof of concept for the certification framework. The Trust’s success underscores both the feasibility and the operational robustness of applying these new IEC standards in real-world clinical environments, setting a precedent for centers around the world.
Charles Crawley, Chair of the JACIE Working Party, underscored the importance of this evolution, asserting that the introduction of the dedicated IEC certification pathway is a natural and necessary extension of JACIE’s core mission — to improve patient outcomes through maintaining stringent quality and certification criteria. He emphasized the framework’s adaptability in supporting ongoing innovation while safeguarding patient safety and maintaining consistency in care delivery protocols across diverse clinical settings.
Debra Josephs, Consultant in Medical Oncology and Early Phase Clinical Trials at Guy’s and St Thomas’ and the IEC Programme Director, echoed this sentiment by recognizing the successful pilot inspection as a critical validation of the certification pathway. She affirmed that the standardized framework is now ready to underpin the next generation of IEC therapy programs, facilitating broader adoption and fostering confidence among healthcare providers and patients alike.
Nisha Shaunak, Head of Programmes, Advanced Therapies at the Trust, highlighted the independent assurance this external assessment brings to their cellular therapy program. According to Shaunak, the certification marks a major milestone for the Trust’s aspirations to expand patient access to IEC treatments across a broad spectrum of future indications, reinforcing the institution’s leadership in cutting-edge therapy delivery.
Importantly, this development signals an invitation to all centers delivering IEC therapies worldwide. By engaging with JACIE’s certification process, institutions can join a growing global network dedicated to quality-driven, evidence-based cellular therapy. This collective commitment is essential to fostering an ecosystem where patient safety and therapeutic efficacy go hand in hand with innovative clinical progress.
The introduction and practical validation of the IEC 3.1 Standards could well accelerate the translation of emerging cellular therapies from experimental stages into routine clinical practice. With increasing numbers of trials exploring applications in solid cancers and autoimmune conditions, this comprehensive quality framework is poised to become a cornerstone in the future expansion of immune effector cell therapies.
In summary, JACIE’s pioneering inspection under the 3rd Edition IEC Standards at Guy’s and St Thomas’ NHS Foundation Trust heralds a transformative chapter for cellular therapy certification. By uniting expert consensus, rigorous process oversight, and clinical validation, this initiative is set to enhance the integrity and scalability of IEC therapies globally, promising improved outcomes for a growing patient population afflicted by complex, life-threatening diseases.
Subject of Research:
Certification and quality standards for Immune Effector Cell (IEC) therapies beyond hematopoietic cell transplantation.
Article Title:
JACIE Achieves First Certification Under 3rd Edition Immune Effector Cell Standards at Guy’s and St Thomas’ NHS Foundation Trust
News Publication Date:
08 May 2026
Web References:
http://www.ebmt.org
Keywords:
Immune Effector Cells, CAR-T therapy, JACIE certification, cellular therapy standards, IEC 3rd Edition Standards, quality assurance, hematological malignancies, solid tumors, autoimmune diseases, clinical certification, stem cell transplantation, patient safety, advanced therapies
